Videos

December 14th, 2018

Silence Therapeutics CEO looks ahead to clinical trial next year and prospects for RNAi

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), sat down with Proactive London's Andrew Scott after taking on the role back in August.